急性粒细胞白血病基因表达谱的研究

Microarray gene expression profiling in acute myeloid leukemia

目的在急性粒细胞白血病M2a亚型的治疗中,首次完全缓解持续时间(CCR)是和预后相关的最重要的指标。运用基因芯片技术,研究拥有不同CCR病人的基因表达谱差异,从而寻找影响AML预后相关基因。方法收集3例CCR6个月内复发(A组)和3例CCR12个月以上(B组)的AML患者初诊时骨髓单个细胞,纯化mRNA,分别用Cy3和Cy5标记,和Agilent Human1B寡核苷酸基因芯片杂交,研究基因表达谱差异。结果在检测的20173个基因中,筛选出共同差异表达基因21个,其中在A组各例都表达上调的基因有10个,同时表达下调的基因有11个。结论 APP等21个基因与采用标准化疗的AML首次完全缓解持续时间有关,这些基因可能成为早期诊断难治性AML和判断预后的指标。

Objective In the treatment of acute myeloid leukemia （AML-M2a）, the first CCR （continuous complete remission） has been one of the most critical indicators to the prognosis of the patients. Using microarray approaches, gene expression profiles have been studied in patients with different CCR, in order to find out the genes relevant to the progresses of the AML. Methods Bone marrow mononuclear cells were collected and used as different experimental groups respectively. Group A composed of three AML patients with CCR〈6 months, while group B composed of three AML patients with CAER〉12 months. mRNAs were purified and labeled with Cy3 and Cy5 respectively, which were used to hybridize against the Agilent human 1B 60mer oligonucleotide micmarrays, Results In the 20173 genes tested, 21 genes were found expressed differentially between these two groups. Of these differentially expressed genes, 10 genes were up-regulated while 11 genes were down-regulated in group A. Conclusion Through microarray studies, 21 genes including APP were found to be differentially expressed in AML patients whom were treated with standard chemotherapy. Theses genes can be early indicators for the diagnosis as well as prognosis of the refractory AML.